By Jaime Llinares Taboada

 

AstraZeneca PLC said Thursday that Imfinzi combined with chemotherapy significantly improved pathologic complete response in patients with resectable lung cancer.

The pharmaceutical company reported positive results from an interim analysis of Phase III trials, as the treatment also caused a significant improvement in major pathologic response.

The trial will continue as planned to assess the additional primary endpoint of event-free survival.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

June 30, 2022 02:28 ET (06:28 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Astrazeneca.